CVE:IGX - IntelGenx Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$0.84 0.00 (0.00 %) (As of 01/20/2019 04:00 PM ET)Previous CloseC$0.84Today's RangeC$0.80 - C$0.8652-Week RangeC$0.62 - C$2.36Volume161,800 shsAverage Volume50,344 shsMarket CapitalizationN/AP/E Ratio-6.61Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0042/2015, INT0043/2015, and INT0044/2016 The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada. Receive IGX News and Ratings via Email Sign-up to receive the latest news and ratings for IGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:IGX Previous Symbol CUSIPN/A Webwww.intelgenx.com Phone514-331-7440Debt Debt-to-Equity Ratio1,880.36 Current Ratio1.41 Quick Ratio1.17Price-To-Earnings Trailing P/E Ratio-6.61 Forward P/E Ratio-8.40 P/E GrowthN/A Sales & Book Value Annual SalesC$2.64 million Price / Sales29.34 Cash FlowC$0.02 per share Price / Cash Flow35.00 Book ValueC$0.01 per share Price / Book140.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees32 Outstanding Shares92,048,896Market CapC$0.00 OptionableNot Optionable IntelGenx Technologies (CVE:IGX) Frequently Asked Questions What is IntelGenx Technologies' stock symbol? IntelGenx Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX." How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (CVE:IGX) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.05) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. The firm had revenue of $0.92 million for the quarter, compared to analyst estimates of $0.30 million. View IntelGenx Technologies' Earnings History. When is IntelGenx Technologies' next earnings date? IntelGenx Technologies is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for IntelGenx Technologies. What price target have analysts set for IGX? 1 brokerages have issued 12 month target prices for IntelGenx Technologies' shares. Their forecasts range from C$1.50 to C$1.50. On average, they expect IntelGenx Technologies' share price to reach C$1.50 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price. View Analyst Price Targets for IntelGenx Technologies. What is the consensus analysts' recommendation for IntelGenx Technologies? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelGenx Technologies. Has IntelGenx Technologies been receiving favorable news coverage? News headlines about IGX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IntelGenx Technologies earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. Who are some of IntelGenx Technologies' key competitors? Some companies that are related to IntelGenx Technologies include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB). Who are IntelGenx Technologies' key executives? IntelGenx Technologies' management team includes the folowing people: Dr. Horst G. Zerbe, Founder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board (Age 72)Mr. Andre Godin CPA, CA, Exec. VP & CFO (Age 55)Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65) How do I buy shares of IntelGenx Technologies? Shares of IGX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is IntelGenx Technologies' stock price today? One share of IGX stock can currently be purchased for approximately C$0.84. What is IntelGenx Technologies' official website? The official website for IntelGenx Technologies is http://www.intelgenx.com. How can I contact IntelGenx Technologies? The company can be reached via phone at 514-331-7440. MarketBeat Community Rating for IntelGenx Technologies (CVE IGX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 42 (Vote Outperform)Underperform Votes: 35 (Vote Underperform)Total Votes: 77MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote "Outperform" if you believe IGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?